• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有种属特异性全身清除率的肝代谢药物的人药代动力学预测的改善。

Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.

机构信息

Research Laboratory for Development, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.

Research Laboratory for Development, Shionogi & Co., Ltd., Toyonaka, Osaka 561-0825, Japan.

出版信息

J Pharm Sci. 2018 May;107(5):1443-1453. doi: 10.1016/j.xphs.2017.12.027. Epub 2018 Jan 10.

DOI:10.1016/j.xphs.2017.12.027
PMID:29331382
Abstract

Accurate prediction of human pharmacokinetics (PK) is important for the choice of promising compounds in humans. As the predictability of human PK by an empirical approach is low for drugs with species-specific PK, the utility of a physiologically based pharmacokinetic (PBPK) model was verified using 16 hepatically metabolized reference drugs. After the prediction method for total clearance (CL) and distribution volume at steady state (Vd) in the conventional PBPK model had been optimized, plasma concentrations following a single oral administration of each reference drug to healthy volunteers were simulated, and the prediction accuracy for human PK was compared between empirical approaches and the optimized PBPK model. In the drugs with low species-specific CL, there was little difference in predictability for maximum concentration (C), time to maximum plasma concentration (T), and area under the curve (AUC) (absolute average fold error: 1.3-2.4). In contrast, the optimized PBPK model predicted C and AUC of the drugs with high species-specific CL with lower absolute average fold error (C and AUC: 2.8 and 3.2, respectively) than those of the empirical approach (C and AUC: 2.6-4.9 and 3.9-10.7, respectively). Therefore, the optimized PBPK model is useful for human PK prediction of drugs with species-specific CL.

摘要

准确预测人体药代动力学(PK)对于在人体中选择有前途的化合物非常重要。由于对于具有物种特异性 PK 的药物,经验方法预测人体 PK 的可预测性较低,因此使用 16 种肝代谢的参考药物验证了生理基于药代动力学(PBPK)模型的实用性。在优化了常规 PBPK 模型中总清除率(CL)和稳态分布容积(Vd)的预测方法后,模拟了每个参考药物单次口服给予健康志愿者后的血浆浓度,并比较了经验方法和优化后的 PBPK 模型对人体 PK 的预测准确性。在具有低物种特异性 CL 的药物中,对于最大浓度(C)、最大血浆浓度时间(T)和曲线下面积(AUC)的预测性差异不大(绝对平均倍误差:1.3-2.4)。相比之下,优化后的 PBPK 模型以较低的绝对平均倍误差(C 和 AUC:分别为 2.8 和 3.2)预测了具有高物种特异性 CL 的药物的 C 和 AUC,而经验方法的预测值(C 和 AUC:分别为 2.6-4.9 和 3.9-10.7)。因此,优化后的 PBPK 模型可用于预测具有物种特异性 CL 的药物的人体 PK。

相似文献

1
Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.具有种属特异性全身清除率的肝代谢药物的人药代动力学预测的改善。
J Pharm Sci. 2018 May;107(5):1443-1453. doi: 10.1016/j.xphs.2017.12.027. Epub 2018 Jan 10.
2
Successful Prediction of Human Pharmacokinetics by Improving Calculation Processes of Physiologically Based Pharmacokinetic Approach.通过改进生理基于药代动力学方法的计算过程成功预测人体药代动力学。
J Pharm Sci. 2019 Aug;108(8):2718-2727. doi: 10.1016/j.xphs.2019.03.002. Epub 2019 Mar 12.
3
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.制药研究和制造商协会(PhRMA)与中国疾病预防控制中心(CPCDC)关于人类药代动力学预测模型的倡议,第4部分:使用和岛方法根据体内临床前数据预测人体血浆浓度-时间曲线
J Pharm Sci. 2011 Oct;100(10):4111-26. doi: 10.1002/jps.22551. Epub 2011 Apr 7.
4
Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics.基于生理的新型葡萄糖激酶激活剂辛格列汀的药代动力学模型的建立:通过体表面积标度法、体外至体内探索及稳态浓度-平均驻留时间法的整合:对其药代动力学机制的理解。
Clin Pharmacokinet. 2018 Oct;57(10):1307-1323. doi: 10.1007/s40262-018-0631-z.
5
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.制药研究和制造商协会(PHRMA)与美国疾病控制与预防中心(CPCDC)关于人体药代动力学预测模型的倡议,第5部分:使用基于生理学的药代动力学建模方法预测人体血浆浓度-时间曲线
J Pharm Sci. 2011 Oct;100(10):4127-57. doi: 10.1002/jps.22550. Epub 2011 May 3.
6
Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.开发一种具有药物特异性比例因子的混合生理基于药代动力学模型,以改善对人体药代动力学的预测。
J Pharm Sci. 2013 Nov;102(11):4193-204. doi: 10.1002/jps.23726. Epub 2013 Sep 9.
7
A physiologically based pharmacokinetic model to predict the pharmacokinetics of highly protein-bound drugs and the impact of errors in plasma protein binding.一种基于生理学的药代动力学模型,用于预测高蛋白结合药物的药代动力学以及血浆蛋白结合误差的影响。
Biopharm Drug Dispos. 2016 Apr;37(3):123-41. doi: 10.1002/bdd.1996.
8
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.应用基于生理学的药代动力学模型模拟 21 种不同化合物的人体静脉内和口服药代动力学。
Clin Pharmacokinet. 2011 May;50(5):331-47. doi: 10.2165/11539680-000000000-00000.
9
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance.制药研究和制造商协会(PhRMA)与美国疾病控制与预防中心(CPCDC)关于人体药代动力学预测模型的倡议,第3部分:人体清除率预测方法的比较评估
J Pharm Sci. 2011 Oct;100(10):4090-110. doi: 10.1002/jps.22552. Epub 2011 May 3.
10
IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.IMI - 口腔生物药剂学工具项目 - 自下而上 PBPK 预测成功评估第 4 部分:改进数据和建模策略下的预测准确性和软件比较。
Eur J Pharm Biopharm. 2020 Nov;156:50-63. doi: 10.1016/j.ejpb.2020.08.006. Epub 2020 Aug 14.

引用本文的文献

1
Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations.用于预测健康人群和疾病人群中氟哌啶醇暴露量的基于生理的药代动力学模型的开发与评估
Pharmaceutics. 2022 Aug 26;14(9):1795. doi: 10.3390/pharmaceutics14091795.